Suppr超能文献

撒哈拉以南非洲地区的青光眼控制策略:临床与卫生经济学证据综述

Glaucoma Control Strategies in Sub-Saharan Africa: A Review of the Clinical and Health Economic Evidence.

作者信息

Smith Andrew F, Negretti Guy, Mascaro Aaron, Bokre Desta, Baker Helen, Dhalla Kazim, Murdoch Ian E

机构信息

a Department of Ophthalmology , King's College London , London , UK.

b MedMetrics Inc ., Ottawa , Canada.

出版信息

Ophthalmic Epidemiol. 2018 Oct-Dec;25(5-6):419-435. doi: 10.1080/09286586.2018.1501499. Epub 2018 Jul 30.

Abstract

PURPOSE

A review of the effectiveness, costs, and cost-effectiveness of detection and treatment strategies for glaucoma control in Sub-Saharan Africa (SSA) was conducted.

METHODS

Detailed searches were performed using the Ovid Medline, Ovid Embase, The Cochrane Library, Web of Science, Scopus, and LILACS databases up to September 2016. The key Medical Subject Heading search terms used included glaucoma, diagnosis, treatment, effectiveness, costs, cost-effectiveness, and Sub-Saharan Africa. Effectiveness was measured as the proportion of study participants with an intra-ocular pressure less than or equal to 22 mmHg.

RESULTS

A total of 5658 records were examined with 48 papers identified. The sensitivity and specificity of portable instruments or smartphone technologies to detect glaucomatous changes ranged from 58.3% to 93.8% and from 82.4% to 96.8%, respectively. The overall effect size for various glaucoma interventions was: 0.39 (95% confidence interval (CI) 0.27-0.54, I = 64.85, p = 0.036) for laser trabeculoplasty; 0.56 (95% CI 0.23-0.84, I = 85.74, p = 0.001) for drainage implant devices; 0.66 (95% CI 0.61-0.71, I = 0.00, p = 0.402) for medical management; and 0.73 (95% CI 0.65-0.80, I = 93.25, p = 0.000) for all other non-drainage tube surgical interventions, including trabeculectomy surgery and the use of anti-metabolites. The mean annual cost of anti-glaucoma drugs across SSA was USD 394, with a mean direct non-medication cost per year of USD 54, and a mean surgical cost per year of USD 283.

CONCLUSIONS

While effective glaucoma control interventions exist, their widespread use and diffusion across SSA remain challenging principally due to low per capita income levels and high glaucoma treatment costs.

摘要

目的

对撒哈拉以南非洲地区(SSA)青光眼控制的检测和治疗策略的有效性、成本及成本效益进行综述。

方法

截至2016年9月,使用Ovid Medline、Ovid Embase、Cochrane图书馆、科学网、Scopus和LILACS数据库进行详细检索。使用的主要医学主题词检索词包括青光眼、诊断、治疗、有效性、成本、成本效益和撒哈拉以南非洲。有效性以眼压小于或等于22 mmHg的研究参与者比例来衡量。

结果

共检查了5658条记录,确定了48篇论文。便携式仪器或智能手机技术检测青光眼性改变的敏感性和特异性分别为58.3%至93.8%和82.4%至96.8%。各种青光眼干预措施的总体效应量为:激光小梁成形术为0.39(95%置信区间(CI)0.27 - 0.54,I = 64.85,p = 0.036);引流植入装置为0.56(95% CI 0.23 - 0.84,I = 85.74,p = 0.001);药物治疗为0.66(95% CI 0.61 - 0.71,I = 0.00,p = 0.402);所有其他非引流管手术干预措施(包括小梁切除术和抗代谢药物的使用)为0.73(95% CI 0.65 - 0.80,I = 93.25,p = 0.000)。撒哈拉以南非洲地区抗青光眼药物的年均成本为394美元,每年的平均直接非药物成本为54美元,每年的平均手术成本为283美元。

结论

虽然存在有效的青光眼控制干预措施,但由于人均收入水平低和青光眼治疗成本高,这些措施在撒哈拉以南非洲地区的广泛应用和推广仍然具有挑战性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验